Literature DB >> 10097916

Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects.

R L Ollerton1, R Playle, K Ahmed, F D Dunstan, S D Luzio, D R Owens.   

Abstract

OBJECTIVE: To determine the day-to-day intraindividual variability of fasting plasma glucose (FPG) in newly diagnosed Caucasian type 2 diabetic subjects. RESEARCH DESIGN AND METHODS: A total of 193 newly diagnosed, previously untreated, Caucasian type 2 diabetic subjects (135 men, 58 women) had FPG measured on two consecutive days (FPG1, FPG2). Ethical approval and subjects' full informed consent were obtained. Subjects fasted for 12 h before each study day and rested for at least 30 min before blood was taken. Plasma glucose was analyzed by a glucose oxidase method with intra- and interassay coefficients of variation (CVs) < 2%. Variability of FPG was assessed by comparison of percentage differences (PDs): PD = 100 (FPG2 - FPG1)/FPG1, with averaged FPG (FPGaver = [FPG1 + FPG2]/2). Biological and analytical variability were determined by use of SD2total = SD2biological + SD2analytical, where SD2analytical approximately equal to 2 x (CVglucose measurement)2. Given normally distributed data with zero mean, 95% of daily percentage differences will be expected to fall within a range of +/- 2 SDtotal.
RESULTS: Subjects were age 54 +/- 10 years (mean +/- SD) and had BMI of 29.3 +/- 5.3 kg/m2. FPG values for both days were 12.2 +/- 3.4 mmol/l (FPG1) and 12.1 +/- 3.3 mmol/l (FPG2), with a mean paired difference (95% CI) of 0.1 (0.0 to 0.3) mmol/l. The variance of these differences increased with increasing FPGaver. The PDs did not exhibit this effect and were normally distributed (mean -0.6% [-1.7 to 0.4]; SD 7.4% [6.8 to 8.3]), giving a 95% variability (2 SD) of 14.8%. Biological variability (2 SDbiological) was 13.7%. No significant difference in PD was found between men and women (mean difference 1.3% [-1.0 to 3.6]; SDmale 7.4%, SDfemale 7.3%; P = 0.62).
CONCLUSIONS: A total of 95% of the FPG values for this group of newly diagnosed type 2 diabetic subjects varied within approximately +/- 15% on a daily basis, with approximately 14% caused by biological variability. As these results are expressed in percentage terms, subjects in the group with higher FPG values are likely to experience larger changes in FPG values measured from day to day. This variability should be considered when using FPG for the diagnosis and/or monitoring of response to treatment in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10097916     DOI: 10.2337/diacare.22.3.394

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  23 in total

1.  Diagnosing diabetes--time for a change?

Authors:  K Borch-Johnsen; S Colagiuri
Journal:  Diabetologia       Date:  2009-09-08       Impact factor: 10.122

Review 2.  Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.

Authors:  Benjamin M Leon; Thomas M Maddox
Journal:  World J Diabetes       Date:  2015-10-10

3.  Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

Authors:  Boris Guiu; Elodie Crevisy-Girod; Christine Binquet; Laurence Duvillard; David Masson; Côme Lepage; Samia Hamza; Denis Krausé; Bruno Verges; Anne Minello; Jean-Pierre Cercueil; Patrick Hillon; Jean-Michel Petit
Journal:  Eur Radiol       Date:  2011-11-20       Impact factor: 5.315

4.  Emerging trends in optical sensing of glycemic markers for diabetes monitoring.

Authors:  Rishikesh Pandey; Narahara Chari Dingari; Nicolas Spegazzini; Ramachandra R Dasari; Gary L Horowitz; Ishan Barman
Journal:  Trends Analyt Chem       Date:  2015-01-01       Impact factor: 12.296

5.  International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 17.152

6.  Fasting plasma glucose in the screening for type 2 diabetes in morbidly obese subjects.

Authors:  Dag Hofsø; Trond Jenssen; Helle Hager; Jo Røislien; Jøran Hjelmesaeth
Journal:  Obes Surg       Date:  2009-12-01       Impact factor: 4.129

7.  Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial.

Authors:  Jin J Zhou; Dawn C Schwenke; Gideon Bahn; Peter Reaven
Journal:  Diabetes Care       Date:  2018-08-06       Impact factor: 19.112

Review 8.  Common standards of basal insulin titration in type 2 diabetes.

Authors:  Sabine Arnolds; Tim Heise; Frank Flacke; Jochen Sieber
Journal:  J Diabetes Sci Technol       Date:  2013-05-01

9.  Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds.

Authors:  Yiling J Cheng; Edward W Gregg; Linda S Geiss; Giuseppina Imperatore; Desmond E Williams; Xinzhi Zhang; Ann L Albright; Catherine C Cowie; Ronald Klein; Jinan B Saaddine
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 17.152

10.  Fasting glucose and HbA1c levels as risk factors for the presence of intracranial atherosclerotic stenosis.

Authors:  Yan-Li Wang; Xin-Yi Leng; Yi Dong; Xiao-He Hou; Lin Tong; Ya-Hui Ma; Wei Xu; Mei Cui; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.